ArticleWorld journal of transplantation2025
Impact of low-level pretransplant donor-specific antibodies detected by the Luminex platform on acute rejection and long-term graft survival.
Article in World journal of transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Luminex platform, where beads are coated with single human leukocyte antigens (HLA), detects HLA antibodies with higher sensitivity and specificity compared to complement-dependent cytotoxicity (CDC) assay and flow cross-match (FCXM). The clinical significance of donor-specific antibodies (DSAs) detected by this method is still under investigation.
aimTo report the impact of low-level pretransplant DSAs detected by the Luminex platform on the rates of acute rejection (AR), allograft function, and long-term graft survival.
methodsThis retrospective study was conducted at the Immunology Department of Sindh Institute of Urology and Transplantation, Karachi, Pakistan between January 2013 and December 2022. During this period 2714 patients were transplanted. Out of these patients 78 (2.9%) patients had low-level DSAs detected by the Luminex flow beads method and were negative by CDC and FCXM with their donors. All recipients received ABO-compatible live-related kidney transplants. All patients had a minimum follow-up of 1 year. Graft rejection rates, graft function, and patient and graft survival were analyzed. The estimated glomerular filtration rate was calculated by the full CKD-EPI formula.
resultsThe mean age of all recipients was 29.57 ± 10.11 years and 34.53 ± 9.09 years for the donors. In 48 (61.5%) patients, the cause of end-stage kidney disease was unknown. DSA against HLA class I was detected in 36 (46.1%) patients, class II in 35 (44.8%) patients, and both class I and II in 7 (8.9%) patients. AR episodes were encountered in 8 (10.3%) cases. Seven (87.5%) had T cell mediated rejection (type IA) and one acute antibody-mediated rejection. Antibody status was re-evaluated at the time of biopsy-proven ARs. Five (62.5%) patients lost their DSAs, while three (37.5%) had persistent DSAs. The mean estimated glomerular filtration rate at 1 year was 80.56 ± 27.48 mL/min/1.73 m
conclusionPatients with pretransplant low-level DSAs on Luminex without CDC and FCXM reactivity had good allograft outcomes at 1 year and 10 years as long as they are induced with biological agents and given potent maintenance immunosuppressants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.